FRANKLIN STREET ADVISORS INC /NC - SUPERNUS PHARMACEUTICALS INC ownership

SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 298 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.

Quarter-by-quarter ownership
FRANKLIN STREET ADVISORS INC /NC ownership history of SUPERNUS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$555
-8.3%
20,1400.0%0.05%
-3.9%
Q2 2023$605
-16.6%
20,140
+0.7%
0.05%
-22.7%
Q1 2023$725
+1.7%
20,0000.0%0.07%
-2.9%
Q4 2022$713
-99.9%
20,0000.0%0.07%
-1.4%
Q3 2022$677,000
+17.1%
20,0000.0%0.07%
+25.5%
Q2 2022$578,000
-10.5%
20,0000.0%0.06%
+5.8%
Q1 2022$646,000
+4.7%
20,000
-5.4%
0.05%
+10.6%
Q4 2021$617,000
-42.4%
21,145
-47.3%
0.05%
-48.4%
Q3 2021$1,071,000
+57.0%
40,145
+81.3%
0.09%
+56.9%
Q2 2021$682,000
+7.9%
22,145
-8.3%
0.06%
-1.7%
Q1 2021$632,000
+4.1%
24,1450.0%0.06%0.0%
Q4 2020$607,000
+20.7%
24,1450.0%0.06%
+9.3%
Q3 2020$503,000
-26.0%
24,145
-15.7%
0.05%
-33.3%
Q2 2020$680,000
+32.0%
28,6450.0%0.08%
+8.0%
Q1 2020$515,000
-24.2%
28,6450.0%0.08%
-6.2%
Q4 2019$679,000
-13.7%
28,6450.0%0.08%
-19.2%
Q3 2019$787,000
-17.0%
28,6450.0%0.10%
-18.9%
Q2 2019$948,000
-5.6%
28,6450.0%0.12%
-12.9%
Q1 2019$1,004,000
+5.4%
28,645
-0.2%
0.14%
-7.3%
Q4 2018$953,000
-35.2%
28,700
-1.7%
0.15%
-24.1%
Q3 2018$1,470,000
-15.9%
29,2000.0%0.20%
-22.0%
Q2 2018$1,748,000
+30.7%
29,2000.0%0.26%
+27.5%
Q1 2018$1,337,000
+14.9%
29,2000.0%0.20%
+14.9%
Q4 2017$1,164,000
-1.0%
29,200
-0.7%
0.17%
-9.8%
Q3 2017$1,176,000
-7.2%
29,4000.0%0.19%
-11.1%
Q2 2017$1,267,000
+30.6%
29,400
-5.2%
0.22%
+26.9%
Q1 2017$970,000
-58.7%
31,000
-66.7%
0.17%
-58.7%
Q4 2016$2,348,000
+2.1%
93,0000.0%0.41%
-1.0%
Q3 2016$2,300,000
+6.1%
93,000
-12.6%
0.42%
+1.7%
Q2 2016$2,167,000
+24.0%
106,375
-7.2%
0.41%
+19.1%
Q1 2016$1,747,000
+4.3%
114,575
-8.1%
0.34%
+4.9%
Q4 2015$1,675,000
-10.3%
124,650
-6.3%
0.33%
-11.1%
Q3 2015$1,867,000
-30.7%
133,075
-16.2%
0.37%
-23.4%
Q2 2015$2,696,000
+52.4%
158,775
+8.5%
0.48%
+49.1%
Q1 2015$1,769,000
+12.8%
146,325
-22.6%
0.32%
+8.7%
Q4 2014$1,568,000
-19.1%
188,975
-15.3%
0.30%
-19.2%
Q3 2014$1,939,000
-18.2%
223,075
+3.1%
0.37%
-18.5%
Q2 2014$2,369,000
+10.4%
216,350
-9.8%
0.45%
+5.3%
Q1 2014$2,145,000
+36.5%
239,900
+15.1%
0.43%
+35.2%
Q4 2013$1,572,000
+22.3%
208,450
+19.0%
0.32%
+10.4%
Q3 2013$1,285,000
+72.9%
175,200
+51.7%
0.29%
+58.2%
Q2 2013$743,000115,5000.18%
Other shareholders
SUPERNUS PHARMACEUTICALS INC shareholders Q4 2017
NameSharesValueWeighting ↓
ASHFORD CAPITAL MANAGEMENT INC 698,676$41,816,0005.51%
Provident Investment Management, Inc. 543,194$32,510,0004.61%
NEUMEIER POMA INVESTMENT COUNSEL LLC 426,250$25,511,0002.37%
KOPP INVESTMENT ADVISORS LLC 41,879$2,506,0002.35%
AlphaOne Investment Services, LLC 126,279$7,558,0002.17%
Ranger Investment Management 468,933$28,066,0001.96%
Bruce & Co., Inc. 158,058$9,459,0001.88%
Penserra Capital Management LLC 244,371$29,030,0001.83%
SHAKER INVESTMENTS LLC/OH 49,642$2,971,0001.83%
Bridge City Capital, LLC 47,795$2,861,0001.81%
View complete list of SUPERNUS PHARMACEUTICALS INC shareholders